Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12076753 | 0.98 | SLC6A3 (0.55) | SIGMAR1SLC6A3HRH3LTA4HMBTD1 | |
| SCHEMBL28626341 | 0.84 | SIGMAR1 (0.53) | SIGMAR1HRH3LTA4HCYP1A2 | |
| SCHEMBL844842 | 0.83 | HRH3 (0.47) | SIGMAR1SLC6A3HRH3MBTD1L3MBTL3 | |
| SCHEMBL10926657 | 0.82 | SIGMAR1 (0.56) | SIGMAR1SLC6A3LTA4HL3MBTL1 | |
| SCHEMBL1741859 | 0.82 | SIGMAR1 (0.56) | SIGMAR1LTA4H | |
| SCHEMBL844945 | 0.81 | HRH3 (0.43) | SIGMAR1SLC6A3HRH3MBTD1L3MBTL3 | |
| SCHEMBL10925676 | 0.80 | CCR3 (0.61) | SIGMAR1 | |
| SCHEMBL5380547 | 0.77 | ALDH1A1 (0.39) | SIGMAR1SLC6A3HRH3MBTD1L3MBTL3 | |
| SCHEMBL10925889 | 0.76 | SIGMAR1 (0.58) | SIGMAR1MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL27645919 | 0.75 | ALDH1A1 (0.39) | SIGMAR1SLC6A3HRH3MBTD1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710048-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| CN-101432281-B | 6-0-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG | 2013-08-28 | — | — | CN | disclosed |
| US-20120225861-A1 | 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| EP-0584192-A1 | PRODRUG ESTERS OF PHENOLIC 2-PIPERIDINO-1-ALKANOLS | PFIZER INC. (US) | 1994-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225861-A1 | 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling | CSF1R, CSF3R, FLT3 | SIGMAR1 654/4885SLC6A3 2291/4885HRH3 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.